Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Fineline Cube Jul 8, 2026
Company Drug

Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis

Fineline Cube Jul 8, 2026
Company Deals

We-Linking Secures Angel Financing for Implantable Brain Computer Interface Development

Fineline Cube Nov 2, 2023

Shenzhen-based company We-Linking, a specialist in implantable brain computer interfaces (BCI), has reportedly raised tens...

Company Drug

Chongqing Precision Biotechnology’s PCAR-19B Receives CDE Nod for Breakthrough Therapy Designation

Fineline Cube Nov 2, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Chongqing Precision Biotechnology Co.,...

Company

Astellas Pharma Inc. Reports Moderate Revenue Growth in H1 Fiscal 2023 Financials

Fineline Cube Nov 2, 2023

Japan-based Astellas Pharma Inc., (TYO: 4503) has released its financial results for the first half...

Company Drug

Sichuan Kelun-Biotech’s SKB264 Receives Priority Review Status for TNBC Treatment in China

Fineline Cube Nov 2, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co.,...

Company Drug

Hinova Pharmaceuticals’ HP518 Receives NMPA Approval for mCRPC Clinical Trial

Fineline Cube Nov 2, 2023

China-based biopharmaceutical company Hinova Pharmaceuticals (SHA: 688302) has announced that it has received clinical trial...

Company Drug

Sino Biopharmaceutical’s TQG3902 Injection Receives NMPA Approval for Septic Shock Clinical Trial

Fineline Cube Nov 2, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biotech company based in China, has announced that...

Company Drug

Sirnaomics’ STP705 Demonstrates Positive Results in Phase I Focal Fat Reduction Study

Fineline Cube Nov 2, 2023

Sirnaomics Ltd (HKG: 2257) has announced positive safety and efficacy results from a Phase I...

Company Deals

3SBio Inc. and CStone Pharmaceuticals Enter Strategic Partnership for Nofazinlimab

Fineline Cube Nov 2, 2023

China-based 3SBio Inc., (HKG: 1530) has announced a strategic partnership and exclusive licensing agreement with...

Company Deals

Resolian Expands Global Reach with Acquisition of China-Based Denali Medpharma

Fineline Cube Nov 2, 2023

US-based bioanalytical contract research organization (CRO) Resolian has announced the acquisition of China-based CRO Denali...

Company Drug

Hainan Poly Pharm Receives FDA Approval for PL002 in Primary Liver Cancer Surgery

Fineline Cube Nov 1, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received clinical...

Company Drug

Changchun BCHT Biotechnology Receives NMPA Approval for Anti-Tetanus Monoclonal Antibody Injection

Fineline Cube Nov 1, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced that it has received clinical...

Company Drug

Shenzhen Chipscreen Biosciences Gets NMPA Approval for Phase I Study of CS32582 in Psoriasis

Fineline Cube Nov 1, 2023

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced that it...

Company Deals

Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round

Fineline Cube Nov 1, 2023

Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million)...

Company Deals

ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development

Fineline Cube Nov 1, 2023

ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100...

Company Drug

Shanghai Henlius Biotech’s HanSiZhuang Shows Positive Results in Phase III ASTRUM-002 Study

Fineline Cube Nov 1, 2023

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company in China, has unveiled positive...

Company Drug

Luye Pharma Group’s Rivastigmine Patch LY03013 Approved by China’s NMPA for Alzheimer’s Treatment

Fineline Cube Nov 1, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...

Company

Bio-Techne Corporation Reports 2% YOY Revenue Growth in Q1 2024 Fiscal Report

Fineline Cube Nov 1, 2023

US-based life sciences service provider Bio-Techne Corporation (NASDAQ: TECH) has released its Q1 report for...

Company Drug

Novartis’ Cosentyx Gains FDA Approval for Hidradenitis Suppurativa Treatment

Fineline Cube Nov 1, 2023

The US Food and Drug Administration (FDA) has issued regulatory approval for Novartis’ (NYSE: NVS)...

Company Deals

AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib

Fineline Cube Nov 1, 2023

China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma...

Company Drug

Roche’s Gene Therapy Elevidys Misses Primary Endpoint in DMD Trial

Fineline Cube Nov 1, 2023

Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) has announced that a Phase III trial for its...

Posts pagination

1 … 476 477 478 … 692

Recent updates

  • Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus
  • Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis
  • Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights
  • Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory
  • Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Company Drug

Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.